A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

6295279 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-03-07

Study Completion Date

2022-05-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Outpatients with at least one dispensing record of any medication will be included in the study. An index date will be assigned to each participant and prescription records for anticholinergics will be used in the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AQUA: Anticholinergic Side Effects QUestionnAire

NCT04791111

Overactive Bladder

COMPLETED

The Effect of Anticholinergics on Cognitive Function in the Elderly

NCT01922115

Mental Competency Urinary Bladder, Overactive Cognitive Function

COMPLETED PHASE4

Reproducibility Study of OABSS and Its Response to Treatment

NCT02667470

Overactive Bladder

COMPLETED PHASE4

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

NCT03572231

Overactive Bladder (OAB)

COMPLETED

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

NCT03602508

Overactive Bladder (OAB)

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Bladder (OAB)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects With Overactive Bladder Treatment

Subjects who have dispensing records for treatment of overactive bladder will be included

Non-Interventional

Intervention Type OTHER

Overview of anticholinergic burden, rather than to evaluate specific drugs

Subjects Without Overactive Bladder Treatment

Subjects who do not have dispensing records for treatment of overactive bladder will be included

Non-Interventional

Intervention Type OTHER

Overview of anticholinergic burden, rather than to evaluate specific drugs

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-Interventional

Overview of anticholinergic burden, rather than to evaluate specific drugs

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have at least one dispensing of any medication between January 22, 2016 and December 31, 2016.

* Have at least one dispensing of any medication between January 1st, 2016 and December 31, 2016.
* Participant was diagnosed with OAB (ICD-10 N32.8, N31.0, N31.1, N31.2, N31.8, N31.9, N32.9, N39.8 and N39.40) at index date.
* Participant did not have dispensing record of an OAB medication during the washout period (6 months prior to the index date).

Exclusion Criteria

* Participants who do not have a complete year of data availability in the database prior to index date.
* Have record of hospitalization on the index date.

* Participant was hospitalized on the index date.
* Participant did not have an active insurance status during the washout period or on the index date.
* Participant received onabotulinumtoxin A and/or surgical intervention as part of the OAB treatment during the washout period.
* Participant was diagnosed with stress incontinence (ICD-10 N39.3 or equivalent) or had dispensing record of medication for stress incontinence (duloxetine) during the washout period.
* Participant was diagnosed with urinary tract infection (ICD-10 N30.0 and N39.0 or equivalent) during the washout period or on the index date.

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No